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Abstract 
Due to overlapping morphology, malignant chromophobe renal cell carcinomas (RCC) 
and benign renal oncocytomas (RO) may pose a diagnostic problem. In the present 
study, we have applied different algorithms to evaluate the data sets obtained by hy-
bridisation of pooled and also individual samples of renal cell tumours (RCT) onto two 
different gene expression platforms. The two approaches revealed high similarities in the 
gene expression profiles of chromophobe RCCs and ROs but also some differences. 
After identifying the differentially expressed genes by statistic analyses, the candidate 
genes were further selected by a real time and normal RT-PCR and their products were 
analysed by immunohistochemistry. We have identified CD82 and S100A1 as valuable 
markers for chromophobe RCC as well as AQP6 for ROs. However, these genes are 
expressed at the protein level in other types of RCTs as well albeit at a low frequency 
and low intensity. As none of the selected genes marks exclusively one type of RCTs, for 
the differential diagnosis of chromophobe RCCs and ROs, a set of markers such as CD82, 
S100A1 and AQP6 as well as some others would be an option in routine histological 
laboratories. 
Key words: chromophobe renal cell carcinoma, gene expression profile, real-time PCR, IHC, di-
agnosis. 
1. Introduction 
Renal cell tumours (RCT) are classified into four 
main types, such as conventional, papillary and 
chromophobe renal cell carcinomas (RCC) and renal 
oncocytomas (RO). Although chromophobe RCCs 
and ROs makes up only 10% of RCTs, their differen-
tial diagnosis is of clinical importance. RO is a benign 
tumour and chromophobe RCC, in spite of excellent 
survival rate of patients, is a malignant tumour. Both 
types of tumours are characterised by pathognomic 
histological pattern, but unusual cellular and growth 
variants are often misdiagnosed on H&E stained 
slides. Chromophobe RCCs display a loss of chro-
mosomes 1, 2, 6, 10, 13, 17 and 21, the detection of 
which may help to establish the correct diagnosis (1); 
for review see (2). However, pathologists prefer to use 
immunohistochemistry as differential diagnostic ap-
proach, which allows to localise the markers to spe-
cific morphology under microscope. Recently, several Int. J. Biol. Sci. 2009, 5 
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studies using microarray technology suggested that 
gene expression pattern may distinguish different 
types of RCTs, but chromophobe RCCs and ROs were 
assigned to one cluster (3-8). Until now, only CD82 
has been described as an appropriate diagnostic 
marker for chromophobe RCC (9-10). 
In pilot study of gene expression profiling we 
used Affymetrix HG-U133 A and B set to characterize 
the transcriptome of distinct types of RCTs in pooled 
samples. In a second setting we have analysed indi-
vidual tumours by applying the Affymetrix HG-U133 
Plus2.0 GeneChip. Genes expressed differentially in 
chromophobe RCCs or ROs were proved by RT-PCR. 
Finally, candidate genes were analysed by immuno-
histochemistry on paraffin-embedded tissue blocks 
and tissue microarrays (TMA).  
2. Material and Methods 
2.1. Tissue samples and RNA isolation 
Tumour and normal kidney tissues were ob-
tained immediately after nephrectomy. A homoge-
neous appearing part of the tumour was divided into 
two parts, one of them was immediately snap frozen 
in liquid nitrogene and stored at -80°C and the an-
other part was processed for histology as reference for 
the frozen material. The rest of tumour and kidney 
was processed for routine histology. The histological 
diagnosis was established according to the Heidelberg 
Classification of Renal Cell Tumours (11). The diag-
nosis of samples used for this study was confirmed by 
SNP- based array analysis (2). The collection and use 
of tissue samples, with the patients’ previous in-
formed consent, was approved by the Ethics Com-
mittee of the University of Heidelberg. 
Total RNA from normal and tumour tissues was 
extracted by TRIzol reagent (Invitrogen GmbH, 
Karlsruhe, Germany) according to the manufacturer’s 
recommendations. The concentration of RNA was 
measured with spectrophotometry. The absence of 
DNA contamination in RNA samples was confirmed 
by PCR using intron-specific primers for of GAPDH.  
2.2. Gene expression profiling and data analysis: 
pooled samples 
We pooled the RNA isolated from five normal 
kidneys, three Wilms’ tumours, three papillary RCC 
without progression (pT1,G1) and two ones with me-
tastatic growth (pT3,G3), five conventional RCCs 
without progression (pT1,G1) and four with deadly 
progression (pT3,G3), and also four chromophobe 
RCCs and three ROs. Total RNA was purified with 
Qiagen RNeasy Mini Kit (QIAGEN GmbH, Hilden, 
Germany). The cRNA synthesis, hybridization onto 
Affymetrix HG-U133 A and B array set (Affymetrix 
Inc., Santa Clara, USA) and first data analysis was 
performed at the German Resource Center for Ge-
nome Research (http://www.rzpd.de). Normalized 
and log2-transformed intensity data (44,928 probe 
sets) as well as corresponding present/absent and 
increased/decreased calls produced by the GCOS 
software (Affymetrix) were further processed using 
Microsoft Excel. The value in the pooled normal adult 
kidney samples was used as a baseline reference and 
relative expression values in pooled tumour samples 
were calculated. The genes that showed an adjusted 
signal log2 ratio above 1 or less than 1 in tumour 
samples were considered to be over- and un-
der-expressed, respectively. 
To compare the expression patterns among renal 
tumour subtypes, the expression profiles were ana-
lyzed by unsupervised hierarchical average linkage 
clustering algorithm supplied with the microarray 
data analysis tool TMEV 
(http://www.tm4.org/mev.html). The process of 
similarity measurements was based on the Pearson 
correlation. To identify genes (approx. 600 probe sets) 
that correlated significantly with chRCC and RO, a 
three fold-change threshold versus other tumour 
subtypes was used in combination with the Affy-
metrix difference call of increase, marginal increase, 
decrease and marginal decrease. Finally, 100 signifi-
cant probe sets were manually selected and the in-
formation about the transcripts that they detect was 
annotated using information obtained from the Af-
fymetrix NETAFFX database (www.affymetrix.com). 
2.3. Gene expression profiling and data analysis: 
individual samples 
In this setting we used high quality RNAs from 
13 conventional RCCs without and 13 with deadly 
progression, 10 papillary RCCs without and 7 papil-
lary RCCs with progression, four chromophobe 
RCCs, four ROs, two collecting duct carcinomas, four 
Wilms’ tumours, one clear cell sarcoma of the kidney, 
one rhabdoid tumour of the kidney, one mucinous 
tubular and spindle cell carcinoma, as well as four 
adult and two fetal normal kidneys. The global gene 
expression profiling by using the Affymetrix 
HG-U133 Plus2.0 GeneChip oligonucleotide mi-
croarray was carried out at the Genomics Core Facil-
ity, EMBL, Heidelberg, Germany. The robust 
multi-array average algorithm of R and RMA imple-
mentation in Bioconductor package 
(http://www.bioconductor.org) was used to perform 
preprocessing of the .CEL files, including background 
adjustment, quartile normalization, and summariza-
tion. Data were further processed using Microsoft 
Excel. Expression measurements were transformed by Int. J. Biol. Sci. 2009, 5 
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computing the base-two logarithm before further 
analysis. Relative expression profiles were generated 
from the individual tumour expression profiles and 
the mean expression values of the four individual 
normal adult kidney expression profiles (53,677 probe 
sets). 
Differential expression between chromophobe 
RCCs and ROs versus all other types of RCTs was 
assessed by ANOVA application supplied by the 
TMEV tool. Probe sets with P value of < 10-4 were 
considered significant. To compare the expression 
patterns among renal tumour subtypes and organize 
the differentially expressed transcripts the average 
linkage unsupervised hierarchical cluster analysis 
(HLC) was performed. The clustering algorithm 
groups both genes and samples by similarity in ex-
pression pattern that was based on the Pearson cor-
relation. The significant analysis of microarrays 
(SAM) based on two-class unpaired analysis and 
available number of permutations was used to derive 
a list of probe sets identified as significantly changed 
(fold change ≥ 2) between chRCC and RO.   
2.4. Functional annotation 
Since the interpretation of the microarray results 
requires the presentation of the data in the context of 
their functional processes and cellular localization, the 
set of patterns identified as differentially expressed in 
chRCC or RO were subgrouped into respective func-
tional categories and according to their cellular local-
ization based on the latest currently available infor-
mation stored in public domain Database for Annota-
tion, Visualization and Integrated Discovery (DAVID, 
http://david.abcc.ncifcrf.gov) and reported 
GOTERM-BP (Biological process), GOTERM -CC 
(cellular component) and GOTERM-MF (molecular 
function) that had corrected P values of <0.01. Al-
though some transcripts have poorly understood 
functions, functional assignments were possible for 
most genes. 
2.5. Quantative RT-PCR 
First strand cDNA synthesis was performed with 
2µg of total RNA using SuperScript II reverse tran-
scriptase (Invitrogen) and oligo-p(dT)23 primer ac-
cording to the manufacturer’s instructions. Real-time 
PCR was performed on a panel of primary RCTs and 
normal kidneys for assessing the relative expression 
of genes of interest and validation of microarray ex-
pression data. Primers were designed to span at least 
on intron of genomic sequence using Primer3 soft-
ware http://frodo.wi.mit.edu/primer3/primer3_ 
code.html and synthesized by MWG-Biotech AG 
(Ebersberg, Germany). The sequences of the 
gene-specific primers used in this study are available 
upon request. Reaction was performed in 15 µl using 6 
μl of cDNA diluted 1:16 and Platinum SYBRGreen 
qPCR SuperMix-UDG (Invitrogen). After activation at 
95 °C for 15 min, PCR product was amplified for 45 
cycles (94°C denaturation for 30 s, 60oC primer an-
nealing for 30 s, and 72°C extension for 45 s) followed 
by an additional 5 min step at 72 °C. Detection of 
product amplification, melting curve analysis and 
semi-quantification was performed by DNA Engine 
Opticon system (MJ Research, Inc., Watertown, USA). 
Relative quantity was calculated by dividing the gene 
specific expression with the expression of β-actin and 
GAPDH and then brought in correspondence with 
100%-scale. All reactions were carried out in dupli-
cates and the results were averaged using statistical 
analysis tools of MS Excel. 
2.6. RT-PCR  
RT-PCR was performed in automated thermal 
cycler (DNA Engine, Biozym Diagnostik GmbH, 
Hess.Oldendorf, Germany) in 15 µl reaction volume 
using 6 µl of cDNA diluted 1:16 and 0.75U Taq poly-
merase (Invitrogen). In preliminary experiments, cy-
cle titration reactions determined numbers of cycles 
required for optimal detection was performed. The 
reaction was done over 30 and 35 cycles; with dena-
turation at 94°C for 30 sec, annealing at 64°C for 30 sec, 
elongation at 72°C for 45 sec and an additional 5 min 
elongation at 72°C. GAPDH was used as the control 
for equal loading and water as the no template. The 
expected band for each product was identified by a 
comigration of a DNA marker ladder electrophoresed 
in an adjacent lane. 
2.7. Western blot analysis 
The proteins were solubilized in the lysis buffer 
(62,5 mM Tris, 2% SDS, 10% sucrose, pH 6,8) con-
taining protease inhibitors (Roche Diagnostics GmbH, 
Mannheim, Germany), and protein concentrations 
were measured by BCA Protein Assay kit (Pierce, 
Rockford, USA). 60 µg of proteins were 
size-fractioned by 12% SDS-PAGE, transferred elec-
trophoretically to a nitrocellulose membrane (Protran, 
Whatman GmbH, Dassel, Germany) and blotted with 
rabbit polyclonal antibody raised against C-terminus 
of AQP6 (AB3073, Millipore GmbH, Schwalbach, 
Germany). An enhanced chemiluminescence (West-
ern Lightning Plus-ECL, PerkinElmer LAS GmbH, 
Rodgau, Germany) system was used for the signal 
detection. The blot was reprobed with anti-β-actin 
antibody (AC-15, SIGMA-Aldrich GmbH, Steinhem, 
Germany) to control for loading.  Int. J. Biol. Sci. 2009, 5 
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2.8. Tissue microarray and immunohistochem-
istry  
Original paraffin blocks of fetal and adult kid-
neys, chromophobe RCCs and ROs as well as tissue 
microarrays containing fetal and adult kidneys and 
distinct types of RCTs were used for this study. TMAs 
with 0,6 mm core biopsies was constructed after 
marking the areas of interest on H&E stained slides by 
one of the authors (GK) by a Manual Tissue Arrayer 
(MTA1, Beecher Instruments, Inc., Sun Prairie, USA).   
The 4 µm sections were deparaffinized in xylene, 
and rehydrated in gradient ethanol. For antigen re-
trieval, heat pretreatment was performed using the 
Biocare pressure cooker (10 mM citrate buffer, pH 
6.0). The sections were subsequently blocked with 
10% normal goat serum (X0907, Dako Cytomation, 
USA) for 1 h, following by the incubation with pri-
mary antibody in a moist chamber at 4oC overnight. 
After endogenous peroxidase was quenched by 0.3% 
H2O2 for 15 min, following by incubation with 
RPH-conjugated secondary antibody (EnVision+ sys-
tem, Dako North America, Inc., Carpinteria, USA) for 
1 h. Visualization of the antigen antibody immunore-
action was completed using AEC (Dako North 
America, Inc.) for 10 min. The sections were counter-
stained with hematoxylin, mounted with aqueous 
permanent mounting medium Ultramount (Dako 
North America, Inc.) and cover-slipped with Pertex 
(Medite GmbH, Burgdorf, Germany). The slides were 
evaluated twice by one of the authors (GK). The fol-
lowing antibodies and dilutions were used: CLDN8 
(1:100, GeneTex Inc., Irvine, USA), TMC5 (1:500, Ab-
cam, Heidelberg, Germany), IHPK3 (1:200, 
Sigma-Aldrich GmbH, Steinhem, Germany), S100A1 
(1:200, Acris Antibodies GmbH, Herford, Germany) 
and AQP6 (1:50, Millipore GmbH, Schwalbach, Ger-
many). 
3. Results 
3.1. Gene expression profiling of pooled samples 
Data obtained from this study are available at 
the Gene Expression Omnibus repository under ac-
cession number GSE6280 (GEO, 
http://www.ncbi.nih.gov/geo/). Unsupervised clus-
tering based on the total gene expression profile re-
vealed variations in up- and down-regulated tran-
scripts among the ten histologically different pools 
(Figure 1A). However, highly similar expression pat-
terns were existed between chromophobe RCC and 
RO pools, as it is shown by the dendogramm ob-
tained. 
We have filtered the expression profiles for 
transcripts expressed with more than three-fold dif-
ference between these groups and obtained an 
approx. 600 probe set. The transcripts were manually 
selected on the basis of the signal log ratio and corre-
sponding present/absent and increased/decreased 
calls and also by taking into account the difference in 
the expression level in other renal tumour types. The 
stringent selection of candidates identified a small 
panel of 50 probe sets, which were differentially up- 
and down-regulated either in chromophobe RCCs or 
in ROs (Figure 2).   
 
 
 
 
Figure 1. Hierarchical clustering tree of the expression profiles of RCTs. (A) Pooled material. Number of samples pooled 
in each group is shown in parenthesis, a and b marks tumours without and with progression, respectively. (B) Individual 
samples of different histological types of renal neoplasia. Overexpressed genes are marked by red and downregulated by 
green colour as indicated in the scale of expression. Although ROs and chromophobe RCCs are designated to the same 
branch of the tree, differences are also recognised. FK – fetal kidney, WT – Wilms’ tumour, CCSK – clear cell sarcoma of 
the kidney, pRCC – papillary RCC, cRCC – conventional RCC, chRCC – chromophobe RCC, RO – renal oncocytoma, LP 
– mucinous tubular and spindle cell carcinoma, CDC – collecting duct carcinoma.  Int. J. Biol. Sci. 2009, 5 
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Figure 2. Top of the fifty differentially expressed probe sets in ROs and chromophobe RCC as identified by microarray 
hybridisation analysis of pooled samples and ordered by relative fold-changes ≥ 3. Green squares indicate transcript levels 
below the mean value; black squares, transcript levels equal to the median normal value; red squares, transcript levels higher 
than the mean value. Genes proved by real time RT-PCR are marked by star. 
 
The probe sets from ROs and chromophobe 
RCCs were placed into the DAVID program, which 
identified statistically significant functional categories 
using Gene Ontology (GO). The analysis showed a 
strong over-expression of genes belonging to the 
cell-cell signalling, cell differentiation, development, 
protein binding and metabolic processes as well as a 
down-regulation of genes encoding intracellular (or-
ganelle) proteins associated with the regulation of 
biological processes in chRCC. Many genes 
up-regulated in RO encode proteins with transmem-
brane transporter activity and playing a role in signal 
transduction and cell communication, whereas intra-
cellular proteins associated with cellular metabolic 
processes and cell proliferation had a lower expres-
sion. 
3.2. Gene expression profiling of individual sam-
ples 
Data of this study are available at the Gene Ex-
pression Omnibus repository under accession number 
GSE11151 (GEO, http://www.ncbi.nih.gov/geo/). 
Using normalized and log2-transformed microarray 
data obtained from distinct types of RCTs including 
four chromophobe RCC and RO approx. 6200 probe 
(12 %) sets were identified by ANOVA with P-value 
of < 10
-4.  A consistent relationship between a gene 
expression pattern and tumour types was detectable 
by unsupervised hierarchical clustering (Figure 1B). 
As chromophobe RCCs and ROs showed overlapping 
clusters, they were identified as one of the major 
branches. Of interest these types of RCT are charac-
terized by the over-expression of genes rather than by 
under-expression.  Int. J. Biol. Sci. 2009, 5 
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The SAM analysis revealed differences between 
chromophobe RCCs and ROs. Among 503 probe sets 
obtained by this approach, including 289 and 214 
transcripts for chromophobe RCC and RO, respec-
tively. After removing the false positive genes by 
reading the data and also by taking into account the 
difference in expression level of the selected genes in a 
given group (all four samples) by comparing with 
others, a discrete set of fifty genes that consistently 
characterize chromophobe RCC and RO was obtained 
(Figure 3). 
 
 
Figure 3. Twenty five genes up- and down-regulated in ROs (A) and chRCC (B) as identified by microarray hybridization 
analysis using individual samples. Each row represents a single probe set, whereas each column represents a single sample. 
The coloured scales at the top represent the expression ratios of genes. Green squares indicate transcript levels below the 
mean value; black squares a transcript level equal to the median normal value and red squares a transcript levels higher than 
the mean value. Genes proved by real time RT-PCR are marked by star. 
 
The selection of genes up-regulated in chromo-
phobe RCC based on their function indicated that a 
significant number of them encode proteins inte-
grated to membrane and related to vesicle-mediated 
transport, protein binding, cell communication and 
metabolic process, whereas proteins encoded by 
down-regulated genes were intracellularly mem-
brane-bounded and involved in regulation of bio-
logical processes. The genes overexpressed in RO en-
code for proteins which are integral to plasma mem-
brane and related to ion transport and cell communi-
cation, whereas under-expressed genes were enriched 
for intracellular or membrane proteins playing a role 
in metabolic processes. 
3.3. Validation of microarray data by RT-PCR 
We performed a SYBR Green-based real-time 
RT-PCR of 61 genes up- or downregulated in chro-
mophobe RCCs (40 genes) and ROs (21 genes) by mi-
croarray analysis using the two approaches (Figure 2 Int. J. Biol. Sci. 2009, 5 
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and 3). Quantitative RT-PCR on the panel of cDNA 
samples including eight individual cases of different 
types of RCTs as well as normal adult kidneys con-
firmed the up-regulation of four genes (CLDN8, 
PRSS8, TFAP2A, TMC5) in chromophobe RCC and 
ten genes (ABCA8, AQP6, DLG2, FAM24B, IHPK3, 
MCOLN2; MCOLN3, NXPH2, PTGFR3, SLC4A9) in 
ROs. We have also identified SCG3, SPINK1 and 
PAK7 as upregulated genes in chromophobe RCCs by 
a n a l y s i s  o f  t h e  p o o l e d  s a m p l e s .  I n  a d d i t i o n  
up-regulation of CD82, RBM35A and TMC5 and 
down-regulation of GLIS3 in chromophobe RCCs and 
upregulation of S100A1 in ROs was selected by array 
analysis of individual samples and real-time RT-PCR.   
To confirm the tumour specific expression of 
genes selected by Affymetrix array and real time 
RT-PCR, we have applied normal RT-PCR using 30 
and 35 cycles of amplification to control the gene ex-
pression on the yes or no basis. We have confirmed 
the differential expression of four genes in chromo-
phobe RCCs (CD82, CLDN8, RBM35A, and TMC5) 
and four genes in ROs (IHPK3, MCOLN2, S100A1, 
AQP6). The CD82 was specifically expressed in 
chromophobe RCCs at RNA and 
protein level (Yusenko and 
Kovacs, 2009). Although the 
CLDN8 was expressed in 18 of 19 
chromophobe RCCs, we have de-
tected a PCR product in 14 of 27 
ROs as well. Consistent with the 
microarray data, RBM35A was 
highly expressed in 17 of 19 chro-
mophobe RCCs whereas only two 
cases of RO showed a strong signal (2/29), 8 cases a 
weak signal (8/29), and the rest of samples (19/29) 
showed no expression of RBM35A. The TMC5 gene 
was expressed in 15 of the 19 chromophobe RCC and 
only in 6 of the 29 ROs with weak signal intensity 
except one case. None of the conventional and papil-
lary RCCs showed the expression of TMC5.  
The IHPK3 and MCOLN2 showed a variable 
expression by RT-PCR in distinct types of RCTs with 
only a slight predominance in ROs (data not shown). 
We found a positive amplification signal of the 
S100A1 in all but one of the 27 ROs, but also in 10 of 
the 19 chromophobe RCCs although with a weak 
signal except two cases (Figure 4A, B). The S100A1 
was also expressed in conventional and papillary 
RCCs as well. By normal PCR, the AQP6 displayed a 
strong amplification product in 21 of 29 RO samples 
and only weak expression in 2 of the 19 chromophobe 
RCCs (Figure 4C, D). No expression of the AQP6 was 
detectable in conventional and papillary RCCs (Figure 
4C). Western blot analysis also confirmed the selective 
expression of AQP6 protein in ROs versus chromo-
phobe RCCs (Figure 4E).   
 
 
Figure 4. Expression of the S100A1 
and AQP6 genes in RCTs and normal 
kidneys. (A) By normal PCR of a panel 
of distinct tumour types, S100A1 was 
positive in ROs and also other types 
of tumours but not in chromophobe 
RCCs. (B) Twenty six of the 27 ROs 
showed a strong amplification signal 
with the S100A1 specific primers. 
Only two of the 19 chromophobe 
RCCs displayed the same intensity 
signal, and 6 further cases showed a 
weak expression. (C) AQP6 was 
over-expressed specifically in ROs as 
compared with other types of renal tumours. Only 4 of the 19 chromophobe RCCs showed a weak expression. (D) The 
AQP6 gene was significantly overexpressed in ROs as compared to corresponding normal kidney tissues. (E) Preferential 
expression of the AQP6 protein in ROs was confirmed by Western blot analysis using tissues (above) and cell extracts 
(below). Variable quantities of cDNA amplification products and proteins among samples were adjusted with GAPDH and 
β-actin, respectively. Int. J. Biol. Sci. 2009, 5 
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3.4. Immunohistochemical findings 
The candidate markers selected by RT-PCR were 
further evaluated by immunohistochemical analysis 
on paraffin-embedded tissue sections and tissue mi-
croarrays using commercially available antibodies. 
An antibody against RBM35A is not available. Im-
munhistochemical studies using original paraffin 
embedded material as well as TMAs did not con-
firmed the differential expression of CLDN8, TMC5 
and IHPK3 between RO and chromophobe RCC. 
Moreover, a weak expression of TMC5 and also 
CLDN8 was seen in conventional and papillary RCCs 
as well. The better staining results were obtained for 
S100A1 and AQP6. The S100A1 was expressed in 68 
(92%) of the 74 ROs and also in 21 (26%) of the 80 
chromophobe RCCs (Figure 5). It was also expressed 
in 55 (62%) of the 88 papillary RCCs and 73 (57%) of 
the 127 conventional RCCs. The AQP6 was positive in 
43 (77%) of the 56 ROs and only 7 (16%) in the 43 
chromophobe RCCs. In addition 2 of the 10 papillary 
RCCs but none of the 10 conventional RCCs showed a 
positive reaction with the AQP6 antibody (Figure 6). 
 
 
Figure 5. Immunohistochemical analysis of S100A1 in normal and tumour tissues. In normal fetal (A) and adult (B) kidneys 
the S100A1 was expressed preferentially in the collecting ducts. (C) A strong diffuse to focal membranous and also cyto-
plasmic staining of RO cells with the S100A1 antibody. Notice that some areas of the RO were negative with the antibody 
(D, below). (E) Some chromophobe RCCs revealed a cytoplasmic staining attenuated to the cell membrane. All pictures are 
of the same microscopic and optical magnification.  Int. J. Biol. Sci. 2009, 5 
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Figure 6. Expression of the AQP6 in normal kidneys and tumour tissues. (A) A strong positive membranous and weak 
cytoplasmic staining in the collecting duct of adult kidney. (B, C) Strong diffuse to focal membranous and also cytoplasmic 
staining of tumour cells was seen in renal oncocytoma. (D) Focal strong staining was observed only in a few chromophobe 
RCC. 
 
4. Discussion 
In the present study, we have applied different 
algorithms to evaluate the data sets obtained by hy-
bridisation of pooled and also individual samples of 
RCTs onto two different Affymetrix platforms. The 
two analyses revealed high similarities in the gene 
expression profiles of chromophobe RCCs and ROs 
but also some differences. Generally, the majority of 
transcripts down-regulated in chromophobe RCCs 
were located predominantly on chromosomes 1, 2, 6, 
10, 13, 17 and 21 which are specifically lost from the 
karyotype of this type of tumour (2). Our finding is in 
agreement with data of a previous study which iden-
tified frequent downward biases (genetic intervals 
that contain a disproportionate number of genes that 
are coordinately up- or down- regulated) for chro-
mosomes 1, 2, 6, 10q and 17q in chRCC (5). 
By applying strict selection criteria, we have 
identified a set of genes up- and down-regulated in 
chromophobe RCCs versus ROs. Because the lack of 
positive staining at immunhistochemical analysis due 
to possible technical error cannot be evaluated itself as 
a diagnostic marker, we have concentrated our study 
to genes overexpressed in one of the tumour types. 
The candidate genes were further selected by a real 
time RT-PCR, normal RT-PCR and immunohisto-
chemistry. We have identified CD82 as a valuable 
marker for chromophobe RCC, the finding which was 
confirmed by Western blotting and immunohisto-
chemistry earlier (10). We found a strong diffuse to 
focal membranous and also weak cytoplasmic stain-
ing of tumour cells in 69 (78%) of the 88 chromophobe 
RCCs whereas all the 90 renal oncocytomas were 
negative for the anti-CD82 antibody (10). Several 
studies suggested that CD82/KAI1 is involved in the 
malignant progression of several but not all types of 
cancer (for review see 12). However, only few studies Int. J. Biol. Sci. 2009, 5 
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have been carried out on tumour tissues using im-
munohistochemistry, and the documentation in these 
studies are not really convincing. 
In this study we have analysed S100A1 and 
AQP6 in details as possible markers for ROs. How-
ever, these genes are expressed at the protein level in 
other types of RCTs as well albeit at a low frequency 
and low intensity. Moreover, in the present study the 
number of S100A1-positively stained chromophobe 
RCCs was higher compared to the literature data from 
the absent expression to weak positivity in chromo-
phobe RCCs (13-15). We have previously identified a 
specific expression of a new splice variant of DLG2 by 
array analysis of pooled material, which might also be 
used for the differential diagnosis in cases with un-
certain diagnosis (16). Recently, some selected anti-
bodies have been used to characterize chromophobe 
RCCs and ROs, but with controversial results. For 
example, ARPP has been suggested as an excellent 
marker for ROs (17). Using the antibody obtained 
from the authors of this paper, we were not able to 
confirm their results (data not shown). Summing up 
the data from the literature and our study, with ex-
ception of CD82, no reliable marker has been identi-
fied for the differential diagnosis of chromophobe 
RCC versus RO. 
Until now, expression profile of more than 300 
RCTs including 36 chromophobe RCCs and 31 ROs 
have been studied by filter and microarray hybridiza-
tion (3-4, 6-8, 18-21). As mRNA expression profile of 
chromophobeRCCs is highly similar to that of ROs, 
there is a poor agreement among reported studies as 
to which genes are differentially regulated in these 
two types of tumours. There is no universal algorithm 
for microarray data management. Even when gene 
expressions from the same data set are calculated with 
different algorithms, only a varying degree of overlap 
of the up- and down-regulated genes was identified. 
This variation was also demonstrated in our study by 
using different array platforms and algorithms. It is 
generally accepted that genome-wide gene expression 
profiling is a powerful technique for identifying di-
agnostic markers or targets for therapy. It might be true 
for some type of tumours but not really for renal cell 
neoplasms. Chromophobe RCCs and ROs are believed 
to develop from cells of the collecting duct system, 
which originate from ureteric bud. Therefore, obtaining 
a high degree of overlap in gene expression profile it is 
not surprising. After analysing of several thousand 
genes by gene arrays, hundreds by RT-PCR and the 
selected genes by immunohistochemistry, only a very 
few genes remained over and even these are not exclu-
sively expressed in one type of tumour (3-4, 6-8, 18-21).  
In conclusion, the number of genes selected by 
the global gene expression analysis and their useful-
ness in the diagnostic pathology is far below the ex-
pectations. As none of the selected genes marks ex-
clusively one type of renal cell tumours, for the dif-
ferential diagnosis of chromophobe RCCs and ROs, a 
set of markers such as CD82, S100A1 and AQP6 as well 
as some others would be an option in routine histo-
logical laboratories. However, based on our previous 
experience, we prefer to apply DNA based tools for the 
diagnosis of chromophobe RCCs and ROs with uncer-
tain histology (1-2, 22-23). 
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